Home > Publications database > Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort. > print

001     275477
005     20240229154942.0
024 7 _ |a 10.1186/s13058-023-01625-4
|2 doi
024 7 _ |a pmid:37069615
|2 pmid
024 7 _ |a pmc:PMC10108482
|2 pmc
024 7 _ |a 1465-5411
|2 ISSN
024 7 _ |a 1465-542X
|2 ISSN
024 7 _ |a altmetric:146077081
|2 altmetric
037 _ _ |a DKFZ-2023-00784
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Le Cornet, Charlotte
|0 P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6
|b 0
|e First author
|u dkfz
245 _ _ |a Postdiagnosis circulating osteoprotegerin and TRAIL concentrations and survival and recurrence after a breast cancer diagnosis: results from the MARIE patient cohort.
260 _ _ |a London
|c 2023
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1681981233_32562
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C020#LA:C020#
520 _ _ |a Experimental studies suggest a role for osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in mammary tumor development and progression. These biomarkers have been minimally investigated with respect to outcomes in breast cancer patients.OPG and TRAIL were evaluated in blood samples collected from 2459 breast cancer patients enrolled in the MARIE study, a prospective population-based patient cohort, at median of 129 days after diagnosis. Participants were between ages 50 and 74 at diagnosis and recruited from 2002 to 2005 in two regions of Germany. Follow-up for recurrence and mortality was conducted through June 2015. Delayed-entry Cox proportional hazards regression was used to assess associations between OPG and TRAIL with all-cause and breast cancer-specific mortality, and recurrence, both overall and by tumor hormone receptor status.Median follow-up time was 11.7 years, with 485 deaths reported (277 breast cancer-specific). Higher OPG concentrations were associated with a higher risk of all-cause mortality (hazard ratio for 1-unit log2-transformed concentration (HRlog2) = 1.24 (95% confidence interval 1.03-1.49). Associations were observed in women diagnosed with ER-PR- tumors or discordant hormone receptor status (ER-PR-, HRlog2 = 1.93 (1.20-3.10); discordant ERPR, 1.70 (1.03-2.81)), but not for women with ER + PR + tumors (HRlog2 = 1.06 (0.83-1.35)). OPG was associated with a higher risk of recurrence among women with ER-PR- disease (HRlog2 = 2.18 (1.39-3.40)). We observed no associations between OPG and breast cancer-specific survival, or for TRAIL and any outcome.Higher circulating OPG may be a biomarker of a higher risk of poor outcome among women diagnosed with ER- breast cancer. Further mechanistic studies are warranted.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Breast cancer survival
|2 Other
650 _ 7 |a Estrogen receptor status
|2 Other
650 _ 7 |a OPG
|2 Other
650 _ 7 |a TRAIL
|2 Other
650 _ 7 |a Osteoprotegerin
|2 NLM Chemicals
650 _ 7 |a Ligands
|2 NLM Chemicals
650 _ 7 |a TNF-Related Apoptosis-Inducing Ligand
|2 NLM Chemicals
650 _ 7 |a Tumor Necrosis Factor-alpha
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Hormones
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Breast Neoplasms: pathology
|2 MeSH
650 _ 2 |a Osteoprotegerin
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Ligands
|2 MeSH
650 _ 2 |a TNF-Related Apoptosis-Inducing Ligand
|2 MeSH
650 _ 2 |a Tumor Necrosis Factor-alpha
|2 MeSH
650 _ 2 |a Apoptosis
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Hormones
|2 MeSH
700 1 _ |a Jung, Audrey Ying-Chee
|0 P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9
|b 1
|e First author
|u dkfz
700 1 _ |a Johnson, Theron S
|0 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
|b 2
|u dkfz
700 1 _ |a Behrens, Sabine
|0 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
|b 3
|u dkfz
700 1 _ |a Obi, Nadia
|b 4
700 1 _ |a Becher, Heiko
|b 5
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 6
|u dkfz
700 1 _ |a Turzanski-Fortner, Renée
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 7
|e Last author
|u dkfz
773 _ _ |a 10.1186/s13058-023-01625-4
|g Vol. 25, no. 1, p. 42
|0 PERI:(DE-600)2041618-0
|n 1
|p 42
|t Breast cancer research
|v 25
|y 2023
|x 1465-5411
909 C O |o oai:inrepo02.dkfz.de:275477
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-03-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-03-30
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-03-30
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-03-30
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BREAST CANCER RES : 2022
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:05:15Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:05:15Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-05-02T09:05:15Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BREAST CANCER RES : 2022
|d 2023-08-26
920 2 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 0 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21